This paper focuses on an overview of the development progress of different cyclin-dependent kinase (CDK) inhibitors. The CDKS are a group of kinases that are indispensable in the cell cycle. However, when it comes to cancer, the cell cycle is not healthy which causes malignancy of the cell that is able to mitosis infinitely. Considering the CDK are a group of molecules that is fundament during mitosis, researchers have developed its inhibitors to inhibit the effect that it has during the cell cycle to postpone the growth of cancer and lead to cancer cell apoptosis. This paper targets on the CDK inhibitors of pan-CDK, CDK4/6, 7, 9, and 12, also introducing their development history and current stages in clinical trials, as well as the drugs related to these CDK inhibitors that are FDA-approved for cancer treatment. In addition, the paper also introduces the future potentials of CDK inhibitors in the treatment and therapy of cancer-related diseases.